Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 341 participants.

Also called NCT06297603

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 341 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06297603
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Brazil, Israel, Mexico, Puerto Rico, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06297603. Randomized; double masking; primary purpose treatment. Start 2024-03-15 (actual); primary completion 2026-10-26 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
Intervention (Drug)
Retatrutide
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct06297603
Content hash
171f12618f5d39df9e11346e1aaa00bb5a765df5d64070fa9e5536b4d36fad80